ARF like GTPase 2 binding protein pseudogene 4Genealiases: []
Q-omics provides the consensus-scored ARL2BPP4 profile across patient tissues and cancer cell-line models. ARL2BPP4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ARL2BPP4 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, ARL2BPP4 RNA expression shows 5,407 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, LUAD, and STAD as cancer lineages where ARL2BPP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL2BPP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL2BPP4 survival associations across molecular data types. ARL2BPP4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL2BPP4 RNA expression–survival associations across cancer types. High ARL2BPP4 expression shows unfavorable associations in THCA, PAAD, LIHC, STAD and GBM, but favorable associations in LUAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for ARL2BPP4 RNA expression.
This table summarizes ARL2BPP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ARL2BPP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL2BPP4 shows lower tumor expression in LUSC and higher tumor expression in LUAD, BRCA and COAD. The LUAD box plot shows higher ARL2BPP4 RNA expression in tumor versus normal tissue (log2 FC = +0.992, t-test p < 0.001).
This table shows molecular features associated with ARL2BPP4 in patient tissues and cancer cell lines. In patient samples, ARL2BPP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
